Colon Cancer - Pipeline Review, H2 2016


#909204

722pages

Global Markets Direct

$ 2500

In Stock

Colon Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer Pipeline Review, H2 2016, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 35, 3, 155 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 46 and 16 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 8
Colon Cancer Overview 9
Therapeutics Development 10
Colon Cancer - Therapeutics under Development by Companies 12
Colon Cancer - Therapeutics under Investigation by Universities/Institutes 23
Colon Cancer - Pipeline Products Glance 26
Colon Cancer - Products under Development by Companies 29
Colon Cancer - Products under Investigation by Universities/Institutes 42
Colon Cancer - Companies Involved in Therapeutics Development 46
Colon Cancer - Therapeutics Assessment 179
Drug Profiles 203
Colon Cancer - Dormant Projects 660
Colon Cancer - Discontinued Products 680
Colon Cancer - Product Development Milestones 681
Appendix 692

List of Tables
Number of Products under Development for Colon Cancer, H2 2016 39
Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2016 40
Number of Products under Development by Companies, H2 2016 41
Number of Products under Development by Companies, H2 2016 (Contd..1) 42
Number of Products under Development by Companies, H2 2016 (Contd..2) 43
Number of Products under Development by Companies, H2 2016 (Contd..3) 44
Number of Products under Development by Companies, H2 2016 (Contd..4) 45
Number of Products under Development by Companies, H2 2016 (Contd..5) 46
Number of Products under Development by Companies, H2 2016 (Contd..6) 47
Number of Products under Development by Companies, H2 2016 (Contd..7) 48
Number of Products under Development by Companies, H2 2016 (Contd..8) 49
Number of Products under Development by Companies, H2 2016 (Contd..9) 50
Number of Products under Development by Companies, H2 2016 (Contd..10) 51
Number of Products under Investigation by Universities/Institutes, H2 2016 52
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 53
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 54
Comparative Analysis by Late Stage Development, H2 2016 55
Comparative Analysis by Clinical Stage Development, H2 2016 56
Comparative Analysis by Early Stage Development, H2 2016 57
Products under Development by Companies, H2 2016 58
Products under Development by Companies, H2 2016 (Contd..1) 59
Products under Development by Companies, H2 2016 (Contd..2) 60
Products under Development by Companies, H2 2016 (Contd..3) 61
Products under Development by Companies, H2 2016 (Contd..4) 62
Products under Development by Companies, H2 2016 (Contd..5) 63
Products under Development by Companies, H2 2016 (Contd..6) 64
Products under Development by Companies, H2 2016 (Contd..7) 65
Products under Development by Companies, H2 2016 (Contd..8) 66
Products under Development by Companies, H2 2016 (Contd..9) 67
Products under Development by Companies, H2 2016 (Contd..10) 68
Products under Development by Companies, H2 2016 (Contd..11) 69
Products under Development by Companies, H2 2016 (Contd..12) 70
Products under Investigation by Universities/Institutes, H2 2016 71
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 72
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 73
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 74
Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 75
Colon Cancer - Pipeline by Adamed Sp z oo, H2 2016 76
Colon Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 77
Colon Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 78
Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016 79
Colon Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 80
Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 81
Colon Cancer - Pipeline by Affimed GmbH, H2 2016 82
Colon Cancer - Pipeline by Agenus Inc, H2 2016 83
Colon Cancer - Pipeline by AGV Discovery SAS, H2 2016 84
Colon Cancer - Pipeline by AIMM Therapeutics BV, H2 2016 85
Colon Cancer - Pipeline by Almac Discovery Ltd, H2 2016 86
Colon Cancer - Pipeline by Ambrx Inc, H2 2016 87
Colon Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 88
Colon Cancer - Pipeline by AndroScience Corp, H2 2016 89
Colon Cancer - Pipeline by Aphios Corp, H2 2016 90
Colon Cancer - Pipeline by Aposense Ltd, H2 2016 91
Colon Cancer - Pipeline by Aptose Biosciences Inc, H2 2016 92
Colon Cancer - Pipeline by AstraZeneca Plc, H2 2016 93
Colon Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 94
Colon Cancer - Pipeline by BCN Biosciences LLC, H2 2016 95
Colon Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 96
Colon Cancer - Pipeline by BioCancell Ltd, H2 2016 97
Colon Cancer - Pipeline by Biogazelle NV, H2 2016 98
Colon Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016 99
Colon Cancer - Pipeline by Blirt SA, H2 2016 100
Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 101
Colon Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016 102
Colon Cancer - Pipeline by Celprogen Inc, H2 2016 103
Colon Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 104
Colon Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 105
Colon Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016 106
Colon Cancer - Pipeline by Cytune Pharma SAS, H2 2016 107
Colon Cancer - Pipeline by CZ BioMed Corp, H2 2016 108
Colon Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 109
Colon Cancer - Pipeline by DEKK-TEC Inc, H2 2016 110
Colon Cancer - Pipeline by Eli Lilly and Company, H2 2016 111
Colon Cancer - Pipeline by EntreChem SL, H2 2016 112
Colon Cancer - Pipeline by EnzymeBioSystems, H2 2016 113
Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 114
Colon Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 115
Colon Cancer - Pipeline by GlycaNova Norway AS, H2 2016 116
Colon Cancer - Pipeline by GlycoMimetics Inc, H2 2016 117
Colon Cancer - Pipeline by Grunenthal GmbH, H2 2016 118
Colon Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016 119
Colon Cancer - Pipeline by Hamlet Pharma AB, H2 2016 120
Colon Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 121
Colon Cancer - Pipeline by Helix BioPharma Corp, H2 2016 122
Colon Cancer - Pipeline by Histogen Inc, H2 2016 123
Colon Cancer - Pipeline by Horizon Pharma Plc, H2 2016 124
Colon Cancer - Pipeline by Idera Pharmaceuticals Inc, H2 2016 125
Colon Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016 126
Colon Cancer - Pipeline by Immunome Inc, H2 2016 127
Colon Cancer - Pipeline by Immunomedics Inc, H2 2016 128
Colon Cancer - Pipeline by Immunotope Inc, H2 2016 129
Colon Cancer - Pipeline by Immupharma Plc, H2 2016 130
Colon Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2016 131
Colon Cancer - Pipeline by Incuron LLC, H2 2016 132
Colon Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2016 133
Colon Cancer - Pipeline by Inflection Biosciences Ltd, H2 2016 134
Colon Cancer - Pipeline by Innopharmax Inc, H2 2016 135
Colon Cancer - Pipeline by Intezyne Technologies Inc, H2 2016 136
Colon Cancer - Pipeline by Ironwood Pharmaceuticals Inc, H2 2016 137
Colon Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2016 138
Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016 139
Colon Cancer - Pipeline by JW Pharmaceutical Corp, H2 2016 140
Colon Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 141
Colon Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 142
Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016 143
Colon Cancer - Pipeline by Lipocure Ltd, H2 2016 144
Colon Cancer - Pipeline by Lupin Ltd, H2 2016 145
Colon Cancer - Pipeline by Lymphocyte Activation Technologies SA, H2 2016 146
Colon Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 147
Colon Cancer - Pipeline by MacroGenics Inc, H2 2016 148
Colon Cancer - Pipeline by MaxiVAX SA, H2 2016 149
Colon Cancer - Pipeline by Meabco A/S, H2 2016 150
Colon Cancer - Pipeline by Medicenna Therapeutics Inc, H2 2016 151
Colon Cancer - Pipeline by Microlin Bio, Inc., H2 2016 152
Colon Cancer - Pipeline by Molecular Targeting Technologies Inc, H2 2016 153
Colon Cancer - Pipeline by MolMed SpA, H2 2016 154
Colon Cancer - Pipeline by Monopar Therapeutics LLC, H2 2016 155
Colon Cancer - Pipeline by Multimmune GmbH, H2 2016 156
Colon Cancer - Pipeline by NormOxys Inc, H2 2016 157
Colon Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016 158
Colon Cancer - Pipeline by Novartis AG, H2 2016 159
Colon Cancer - Pipeline by Omeros Corp, H2 2016 160
Colon Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016 161
Colon Cancer - Pipeline by Oncovir Inc, H2 2016 162
Colon Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 163
Colon Cancer - Pipeline by Orega Biotech SAS, H2 2016 164
Colon Cancer - Pipeline by OSE Immunotherapeutics, H2 2016 165
Colon Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 166
Colon Cancer - Pipeline by Patrys Ltd, H2 2016 167
Colon Cancer - Pipeline by PharmaCyte Biotech Inc, H2 2016 168
Colon Cancer - Pipeline by Pharminox Ltd, H2 2016 169
Colon Cancer - Pipeline by Philogen SpA, H2 2016 170
Colon Cancer - Pipeline by Pique Therapeutics, H2 2016 171
Colon Cancer - Pipeline by Plexxikon Inc, H2 2016 172
Colon Cancer - Pipeline by ProNAi Therapeutics Inc, H2 2016 173
Colon Cancer - Pipeline by Provecs Medical GmbH, H2 2016 174
Colon Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 175
Colon Cancer - Pipeline by Qu Biologics Inc, H2 2016 176
Colon Cancer - Pipeline by Recce Pty Ltd, H2 2016 177
Colon Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 178
Colon Cancer - Pipeline by Rgenix Inc, H2 2016 179
Colon Cancer - Pipeline by Sareum Holdings Plc, H2 2016 180
Colon Cancer - Pipeline by Savoy Pharmaceuticals Inc, H2 2016 181
Colon Cancer - Pipeline by Sellas Inc, H2 2016 182
Colon Cancer - Pipeline by Sigma-Tau SpA, H2 2016 183
Colon Cancer - Pipeline by Sirnaomics Inc, H2 2016 184
Colon Cancer - Pipeline by SOM Biotech SL, H2 2016 185
Colon Cancer - Pipeline by Somantix BV, H2 2016 186
Colon Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016 187
Colon Cancer - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016 188
Colon Cancer - Pipeline by Starpharma Holdings Ltd, H2 2016 189
Colon Cancer - Pipeline by Sunshine Biopharma Inc, H2 2016 190
Colon Cancer - Pipeline by Synergys Biotherapeutics Inc, H2 2016 191
Colon Cancer - Pipeline by TaiRx Inc, H2 2016 192
Colon Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2016 193
Colon Cancer - Pipeline by Takis Srl, H2 2016 194
Colon Cancer - Pipeline by Targovax ASA, H2 2016 195
Colon Cancer - Pipeline by Transgene Biotek Ltd, H2 2016 196
Colon Cancer - Pipeline by TVAX Biomedical Inc, H2 2016 197
Colon Cancer - Pipeline by Tyg Oncology Ltd, H2 2016 198
Colon Cancer - Pipeline by TyrNovo Ltd, H2 2016 199
Colon Cancer - Pipeline by Vaccinogen Inc, H2 2016 200
Colon Cancer - Pipeline by Vault Pharma Inc, H2 2016 201
Colon Cancer - Pipeline by Vaxenta Biotechnologies, H2 2016 202
Colon Cancer - Pipeline by Vaximm AG, H2 2016 203
Colon Cancer - Pipeline by VG Life Sciences Inc, H2 2016 204
Colon Cancer - Pipeline by Yakult Honsha Co Ltd, H2 2016 205
Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2016 206
Colon Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2016 207
Assessment by Monotherapy Products, H2 2016 208
Assessment by Combination Products, H2 2016 209
Number of Products by Stage and Target, H2 2016 211
Number of Products by Stage and Mechanism of Action, H2 2016 220
Number of Products by Stage and Route of Administration, H2 2016 229
Number of Products by Stage and Molecule Type, H2 2016 231
Colon Cancer - Dormant Projects, H2 2016 689
Colon Cancer - Dormant Projects (Contd..1), H2 2016 690
Colon Cancer - Dormant Projects (Contd..2), H2 2016 691
Colon Cancer - Dormant Projects (Contd..3), H2 2016 692
Colon Cancer - Dormant Projects (Contd..4), H2 2016 693
Colon Cancer - Dormant Projects (Contd..5), H2 2016 694
Colon Cancer - Dormant Projects (Contd..6), H2 2016 695
Colon Cancer - Dormant Projects (Contd..7), H2 2016 696
Colon Cancer - Dormant Projects (Contd..8), H2 2016 697
Colon Cancer - Dormant Projects (Contd..9), H2 2016 698
Colon Cancer - Dormant Projects (Contd..10), H2 2016 699
Colon Cancer - Dormant Projects (Contd..11), H2 2016 700
Colon Cancer - Dormant Projects (Contd..12), H2 2016 701
Colon Cancer - Dormant Projects (Contd..13), H2 2016 702
Colon Cancer - Dormant Projects (Contd..14), H2 2016 703
Colon Cancer - Dormant Projects (Contd..15), H2 2016 704
Colon Cancer - Dormant Projects (Contd..16), H2 2016 705
Colon Cancer - Dormant Projects (Contd..17), H2 2016 706
Colon Cancer - Dormant Projects (Contd..18), H2 2016 707
Colon Cancer - Dormant Projects (Contd..19), H2 2016 708
Colon Cancer - Discontinued Products, H2 2016 709

List of Figures
Number of Products under Development for Colon Cancer, H2 2016 39
Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2016 40
Number of Products under Development by Companies, H2 2016 41
Number of Products under Investigation by Universities/Institutes, H2 2016 52
Comparative Analysis by Clinical Stage Development, H2 2016 56
Comparative Analysis by Early Stage Products, H2 2016 57
Assessment by Monotherapy Products, H2 2016 208
Assessment by Combination Products, H2 2016 209
Number of Products by Top 10 Targets, H2 2016 210
Number of Products by Stage and Top 10 Targets, H2 2016 210
Number of Products by Top 10 Mechanism of Actions, H2 2016 219
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 219
Number of Products by Top 10 Routes of Administration, H2 2016 228
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 228
Number of Products by Top 10 Molecule Types, H2 2016 230
Number of Products by Stage and Top 10 Molecule Types, H2 2016 230